Abixa10 mg

Abixa is an FDA-approved and guideline-supported treatment for the following:

Established/FDA-approved use

• Treatment of moderate to severe dementia of the Alzheimer's type (Alzheimer's disease).

Guideline-supported / combination use

• Used as monotherapy or, commonly, as add-on (combination) therapy together with a cholinesterase inhibitor (e.g., donepezil) in patients with moderate to severe Alzheimer's disease, a combination supported by clinical guidelines and widely used in practice.

Off-label use

• Abixa has been used off-label in other dementia subtypes (e.g., vascular dementia) and in certain neuropsychiatric or neuropathic pain conditions; evidence for these uses is limited and they are not FDA-approved indications.

Abixa provides symptomatic benefit only; it does not stop or reverse the underlying neurodegenerative disease process, and the overall magnitude of clinical benefit is generally modest.

Abixa is a moderate-affinity, uncompetitive (open-channel) N-methyl-D-aspartate (NMDA) receptor antagonist. It is chemically distinct from cholinesterase inhibitors used in Alzheimer's disease and works through a different pharmacological mechanism.

Abixa is available in immediate-release tablet and oral solution forms, and as an extended-release capsule for once-daily dosing, and is used long-term as part of the symptomatic management of moderate to severe Alzheimer's disease.

Abixa belongs to the therapeutic class of anti-dementia agents, specifically the NMDA receptor antagonist class, distinct from the cholinesterase inhibitor class of anti-dementia drugs.

Memantine Hydrochloride acts as a low-to-moderate affinity, uncompetitive NMDA receptor antagonist. Persistent activation of NMDA receptors by glutamate is thought to contribute to the symptoms of Alzheimer's disease. By binding preferentially to open NMDA receptor-associated cation channels, Memantine Hydrochloride blocks the excessive, pathological glutamatergic activity implicated in neuronal dysfunction, while allowing normal physiological neurotransmission needed for learning and memory to proceed relatively unimpeded.

Memantine Hydrochloride is well absorbed orally, undergoes minimal hepatic metabolism, and is eliminated predominantly unchanged by the kidneys via active tubular secretion, which is pH-dependent. Its elimination half-life is approximately 60-80 hours.

Clinically significant, well-verified interactions with Abixa include:

• Other NMDA receptor antagonists (amantadine, ketamine, dextromethorphan): Concomitant use should generally be avoided, as it may increase the risk of CNS adverse effects such as confusion, agitation, or hallucinations due to additive NMDA-antagonist activity.
• Drugs that alkalinize the urine (e.g., carbonic anhydrase inhibitors such as acetazolamide, sodium bicarbonate, and certain diets): These can reduce renal clearance of Abixa, potentially raising plasma levels and increasing the risk of adverse effects; concomitant use warrants monitoring.
• Drugs eliminated by the same renal cationic transport system (e.g., cimetidine, ranitidine, quinidine, nicotine): Theoretical potential for altered plasma levels of either drug; clinical significance is generally limited but caution is reasonable.

Adverse effects of Abixa are generally mild.

Common (may affect more than 1 in 100 people)

• Dizziness
• Headache
• Confusion
• Constipation
• Fatigue/somnolence

Less common

• Hallucinations
• Anxiety
• Increased muscle tone/hypertonia
• Vomiting
• Elevated blood pressure
• Urinary tract infection

Rare but serious

• Seizures (see Precautions and Warnings)
• Hypersensitivity reactions

Abixa should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should always be consulted before use in pregnancy, as human data remain limited. It is not known whether Abixa passes into human breast milk; because many drugs are excreted in breast milk and effects on a nursing infant cannot be ruled out, a decision should be made in consultation with a physician whether to discontinue nursing or discontinue the drug.

Abixa should be used with caution in the following situations:

• Severe renal impairment: Dose reduction is required (see Dosage and Administration), as memantine is primarily renally cleared.
• Conditions that raise urine pH: Renal tubular acidosis, severe urinary tract infections, and certain diets can reduce renal clearance of Abixa and raise plasma levels; monitor closely in these situations.
• Seizure disorders: Abixa has not been systematically evaluated in patients with a seizure disorder; it may theoretically lower the seizure threshold, though it is generally well tolerated.
• Genitourinary conditions: Conditions that alkalinize urine may need monitoring as above.
• Driving and operating machinery: Abixa may affect concentration and reaction time; patients should be cautious with driving or operating machinery until they know how the medicine affects them.

Abixa provides symptomatic treatment only and does not alter the underlying progressive course of Alzheimer's disease.

Reported overdose experience with Abixa is limited; symptoms may include restlessness, psychosis, visual hallucinations, drowsiness, and other CNS effects. There is no specific antidote. In case of suspected overdose of Abixa, seek immediate medical attention or contact a poison control center / emergency services without delay. Management is supportive and symptomatic, to be carried out by qualified medical personnel.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment

Dose adjustment of Abixa is required in severe renal impairment (target dose reduced to 5 mg twice daily for immediate-release formulations); use with caution and monitor in moderate renal impairment. See Dosage and Administration.

Hepatic impairment

No dosage adjustment is generally needed in mild-to-moderate hepatic impairment; caution is advised in severe hepatic impairment, and Abixa has not been extensively studied in this population.

Elderly

Abixa is primarily used in elderly patients with Alzheimer's disease; no specific dose adjustment based on age alone is required beyond standard renal-function-based adjustment, since renal function commonly declines with age.

Pediatric

Safety and efficacy of Abixa have not been established in children; its use is not recommended in this population.

NMDA receptor antagonist; anti-dementia agent.

Memantine Hydrochloride works as a moderate-affinity, uncompetitive NMDA receptor antagonist. It binds preferentially to open NMDA-receptor-gated calcium channels, blocking pathologically sustained, low-level activation of these receptors by excess glutamate that is believed to contribute to neuronal dysfunction and cognitive decline in Alzheimer's disease, while permitting normal, transient glutamatergic signaling required for physiological learning and memory processes.

B

The safety and efficacy of Abixa have not been established in pediatric patients. Abixa is not indicated or recommended for use in children or adolescents, as Alzheimer's disease is a condition of older adults and no pediatric dosing has been established.